IN THE TREATMENT OF FUNGAL INFECTION

COMPOSITION

Itraconazole BP 65mg/BP 130mg (Supra Bioavailable) Capsules

INDICATION

• Dermatomycosis
• Tinea infections
•  Blastomycosis
•  Chromomycosis
•  Sporotrichosis
•  Paracoccidioidomycosis

Itrazest-SB130

• The orally active antifungal approved by the US-FDA for treating blastomycosis, histoplasmosis, and aspergillosis
•  Shows a 21% reduced variable bioavailability in comparison to conventional ITZ..
•  Maintains consistently elevated serum levels, improving effectiveness against persistent dermatophytosis.
•  Shows a 180% relative bioavailability compared to C-ITZ and an absolute bioavailability of up to 90%.
•  Achieves an equivalent therapeutic effect with half the dosage compared to conventional Itraconazole.
•  Exhibits safety and tolerability compared to C-ITZ